Profiling peripheral microRNAs in obesity and type 2 diabetes mellitus

APMIS

Volumn 123, Issue 7, 2015, Pages 580-585

  Wu, Liangping ^a   Dai, Xiaojiang ^a   Zhan, Junfang ^b   Zhang, Yuxin ^a   Zhang, Hongbin ^a   Zhang, Hongbing ^a   Zeng, Songhua ^a   Xi, Wenbin ^a  

^a GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^b GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Diabetes; MicroRNA; Obesity

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MICRORNA; MICRORNA 138; MICRORNA 150; MICRORNA 152; MICRORNA 17; MICRORNA 205; MICRORNA 376A; MICRORNA 432 5P; MICRORNA 500A; MICRORNA 593; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIRN138 MICRORNA, HUMAN; MIRN152 MICRORNA, HUMAN; MIRN17 MICRORNA, HUMAN; MIRN593 MICRORNA, HUMAN;

ADULT; ARTICLE; AUTOANALYZER; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIET RESTRICTION; GENE IDENTIFICATION; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; BODY MASS; CASE CONTROL STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NORMAL HUMAN; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEALTHY VOLUNTEERS; HUMANS; INSULIN; MICRORNAS; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 84932198447     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12389     Document Type: Article

References (21)

1. Park MH, Falconer C, Viner RM, Kinra S. The impact of childhood obesity on morbidity and mortality in adulthood: a systematic review. Obes Rev 2012;13:985-1000.
2. Chen X, Wei S, Yang F. Mitochondria in the pathogenesis of diabetes: a proteomic view. Protein Cell 2012;3:648-60.
3. Avrahami D, Kaestner KH. Epigenetic regulation of pancreas development and function. Semin Cell Dev Biol 2012;23:693-700.
4. Liu J, Albrecht AM, Ni X, Yang J, Li M. Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways. Curr Mol Med 2013;13:352-7.
5. Pers YM, Jorgensen C. MicroRNA in 2012: biotherapeutic potential of microRNAs in rheumatic diseases. Nat Rev Rheumatol 2013;9:76-8.
6. Fernandez-Hernando C, Ramirez CM, Goedeke L, Suarez Y. MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol 2013;33:178-85.
7. Ishida M, Shimabukuro M, Yagi S, Nishimoto S, Kozuka C, Fukuda D, et al. MicroRNA-378 regulates adiponectin expression in adipose tissue: a new plausible mechanism. PLoS ONE 2014;9:e111537.
8. Ortega FJ, Mercader JM, Catalan V, Moreno-Navarrete JM, Pueyo N, Sabater M, et al. Targeting the circulating microRNA signature of obesity. Clin Chem 2013;59:781-92.
9. Wang X, Sundquist J, Zoller B, Memon AA, Palmer K, Sundquist K, et al. Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE 2014;9:e86792.
10. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010;107:810-7.
11. Pescador N, Perez-Barba M, Ibarra JM, Corbaton A, Martinez-Larrad MT, Serrano-Rios M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS ONE 2013;8:e77251.
12. Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, et al. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Cancer Lett 2015;359:75-86.
13. Yang JS, Li BJ, Lu HW, Chen Y, Lu C, Zhu RX, et al. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol 2014; doi: 10.1007/s13277-014-2938-1.
14. Huang H, Hu M, Li P, Lu C, Li M. Mir-152 inhibits cell proliferation and colony formation of CD133 liver cancer stem cells by targeting KIT. Tumour Biol 2014;36:921-8.
15. Miao CG, Yang YY, He X, Huang C, Huang Y, Qin D, et al. MicroRNA-152 modulates the canonical Wnt pathway activation by targeting DNA methyltransferase 1 in arthritic rat model. Biochimie 2014;106:149-56.
16. Nielsen LB, Wang C, Sorensen K, Bang-Berthelsen CH, Hansen L, Andersen ML, et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012;2012:896362.
17. Chen P, Zeng M, Zhao Y, Fang X. Upregulation of Limk1 caused by microRNA-138 loss aggravates the metastasis of ovarian cancer by activation of Limk1/cofilin signaling. Oncol Rep 2014;32:2070-6.
18. Fischer J, Rossetti S, Datta A, Eng K, Beghini A, Sacchi N. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia. Mol Cancer 2015;14:7.
19. Li H, Gupta S, Du WW, Yang BB. MicroRNA-17 inhibits tumor growth by stimulating T-cell mediated host immune response. Oncoscience 2014;1:531-9.
20. Hu Y, Wang Q, Wang Z, Wang F, Guo X, Li G. Circulating microRNA profiles and the identification of miR-593 and miR-511 which directly target the PROP1 gene in children with combined pituitary hormone deficiency. Int J Mol Med 2015;35:358-66.
21. Huang B, Li H, Huang L, Luo C, Zhang Y. Clinical significance of microRNA 138 and cyclin D3 in hepatocellular carcinoma. J Surg Res 2015;193:718-23.